相关临床试验
19
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2020
进行中（未招募）
7
36.8%
已完成
4
21.1%
招募中
8
42.1%
暂无批准数据
- Xencor reported second quarter 2026 financial results, including $51.2 million in revenue and a net loss of $21.7 million, while advancing its wholly owned clinical pipeline. - Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma were accepted for a proffered paper oral presentation at ESMO Congress 2026 in Madrid. - XmAb541 monotherapy showed an approximate 14% overall response rate in ovarian cancer and 28% in germ cell tumors, supporting prioritization of its combination with XmAb808. - The U.S. FDA granted Fast Track designation to XmAb541 in July 2026 for germ cell tumors relapsed or refractory after two or more lines of platinum therapy.
- Zenas BioPharma has dosed the first subject in a Phase 1 clinical trial of ZB021, a novel oral small molecule IL-17AA/AF inhibitor developed in partnership with InnoCare Pharma. - ZB021 represents the first oral IL-17 inhibitor to enter clinical development globally, potentially offering advantages over current biologic therapies in terms of convenience and accessibility. - The Phase 1 study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers, with data expected by year-end 2026 and proof-of-concept results in psoriasis patients anticipated in 2027. - The company believes the well-validated IL-17 mechanism may enable direct advancement from proof-of-concept to registration-directed trials, potentially accelerating regulatory approval.
- Zenas BioPharma announced positive Phase 3 INDIGO trial results for obexelimab in treating IgG4-related disease, marking a significant clinical milestone for the company. - CEO Leon Moulder made a substantial share purchase following the positive data readout, demonstrating leadership confidence in the company's prospects. - The company maintains a strong financial position with $301.6 million in cash and runway extending into late 2026, supporting continued pipeline advancement. - Previous Phase 2 MoonStone MS results showed obexelimab achieved 95% lesion reduction with a clean safety profile, de-risking the multi-indication platform.
- Obexelimab met its primary endpoint with a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo in the Phase 2 MoonStone trial for relapsing multiple sclerosis (p=0.0009). - The bifunctional monoclonal antibody demonstrated near-complete suppression of inflammatory brain lesions by week 8, with sustained effects through week 12 of treatment. - The safety profile remained consistent with previous trials, and Zenas plans to report 24-week data in Q1 2026 to evaluate potential impact on disability progression. - The company is advancing obexelimab across multiple autoimmune diseases, with Phase 3 results in IgG4-Related Disease expected by year-end 2025.
- Zenas BioPharma has acquired three experimental autoimmune medicines from China's InnoCare Pharma, including orelabrutinib for multiple sclerosis that has already entered Phase 3 testing. - The deal includes up to $100 million in upfront payments and could reach over $2 billion total value for InnoCare, reflecting the growing trend of U.S. companies licensing Chinese drug innovations. - Zenas secured additional $120 million financing to fund operations through Q4 2026, while planning to initiate a second Phase 3 trial for orelabrutinib in secondary progressive multiple sclerosis next year.
- Zenas BioPharma acquired global development and commercialization rights to orelabrutinib, a highly selective CNS-penetrant BTK inhibitor, from InnoCare Pharma in a license agreement potentially worth over $2 billion. - The company has initiated a Phase 3 trial for Primary Progressive MS and plans to start a second Phase 3 trial for Secondary Progressive MS in Q1 2026, targeting the highest unmet medical need in MS. - Previous Phase 2 data showed orelabrutinib significantly reduced new brain lesions in Relapsing-Remitting MS patients, with sustained reductions in inflammatory activity through 96 weeks. - The deal also includes rights to two additional autoimmune candidates and is supported by $120 million in private placement financing to fund operations through Q4 2026.
- Zenas BioPharma and Royalty Pharma announced a $300 million funding partnership to advance obexelimab development for IgG4-Related Disease and other autoimmune conditions. - The deal includes an initial $75 million payment with additional milestone-based payments tied to Phase 3 INDIGO trial results and FDA approvals for IgG4-RD and SLE. - Obexelimab is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb that inhibits B cell function without depleting cells, representing a novel approach to autoimmune disease treatment. - The funding supports potential commercial launch in the first half of 2027 and extends Zenas' cash runway through Q1 2027, with key trial readouts expected by year-end 2025.
• The FDA has approved Amgen's UPLIZNA (inebilizumab-cdon) as the first and only targeted treatment specifically for IgG4-related disease, following positive results from the Phase III MITIGATE trial. • The MITIGATE trial demonstrated an 87% reduction in disease flare risk compared to placebo, with the study enrolling 135 adults across 80 sites in 22 countries. • Multiple companies including Sanofi and Zenas BioPharma are advancing a robust pipeline of approximately 10 therapies for IgG4-related disease, potentially transforming treatment options for this rare inflammatory condition.
- Novo Nordisk undergoes significant executive restructuring following the departure of EVP Camilla Sylvest, with rare disease leader Ludovic Helfgott taking over expanded commercial strategy responsibilities. - Galapagos faces major leadership transition as CEO Paul Stoffels announces retirement plans while CFO Thad Huston departs, amid the company's ongoing transformation into a cell therapy-focused biotech. - Multiple biotechs including Hansa Biopharma, Creyon Bio, and Sutro Biopharma appoint new CEOs as the industry continues strategic realignment efforts. - Emerging companies across oncology, rare diseases, and AI-driven drug development strengthen their leadership teams with experienced executives from major pharmaceutical companies.
• Zenas Biopharma has initiated MoonStone, a Phase 2 clinical trial evaluating obexelimab, a unique B-cell targeting therapy administered weekly via subcutaneous injection in relapsing multiple sclerosis patients. • The trial will enroll 93 participants across 40+ sites globally, targeting adults aged 18-60 with relapsing-remitting MS or active secondary progressive MS, with results expected in Q3 2025. • Unlike current B-cell therapies, obexelimab targets CD19 and FcgammaRIIb proteins to reduce B-cell activity without depleting them, potentially offering a broader therapeutic approach than existing CD20-targeting treatments.
